NDAORALTABLET
Approved
May 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
4/8 — Partial
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FARESTON (toremifene citrate) is an oral selective estrogen receptor modulator (SERM) approved for the treatment of metastatic breast cancer in postmenopausal women. It functions as a non-steroidal antiestrogen that competitively binds to estrogen receptors, inhibiting tumor cell proliferation in hormone receptor-positive breast cancers.
$0.088BPart D
LOE ApproachingDeclining
Declining commercial trajectory with minimal market penetration signals a shrinking team focused on legacy maintenance rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer
Started Mar 2011
0Risk of Bone Fracture Occurrences
Career Relevance
FARESTON offers limited career growth potential as a LOE-approaching legacy product with minimal linked job openings and declining market presence. Professionals joining this team should expect a small, maintenance-focused organization prioritizing cost management and managed market defense rather than innovation and expansion.
Brand Manager
Worked on FARESTON at Inpharmus? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.